Novartis Ag (NVS) Change in Accured Expenses (2022 - 2025)

Novartis Ag's Change in Accured Expenses history runs 4 years deep, the most recent figure standing at $247.0 million for Q4 2025.

• In Q4 2025, Change in Accured Expenses rose 152.55% year-over-year to $247.0 million; the TTM figure through Dec 2025 stood at $545.0 million (up 2695.24% YoY), while the FY2025 annual figure was $247.0 million, changed N/A from the prior year.
• Change in Accured Expenses came in at $247.0 million for Q4 2025 at Novartis Ag, down from $952.0 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $952.0 million in Q3 2025 to a low of -$584.0 million in Q1 2022.
• A 4-year average of $161.4 million and a median of $86.5 million in 2023 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses sank 251.35% in 2024 and soared 152.55% in 2025, its largest moves.
• Novartis Ag's Change in Accured Expenses stood at $498.0 million in 2022, then slumped by 114.86% to -$74.0 million in 2023, then plunged by 535.14% to -$470.0 million in 2024, then jumped by 152.55% to $247.0 million in 2025.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $247.0 million, $952.0 million, and -$184.0 million for Q4 2025, Q3 2025, and Q1 2025 respectively.

Peer Comparison